Top

Published in:

01-12-2021 | Mastectomy | Breast Oncology

Why Breast-Conserving Therapy Should be Considered Treatment of Choice in Early-Stage Breast Cancer Patients

Authors: Casimir A. E. Kouwenberg, MD, MSc, Leonieke W. Kranenburg, PhD, Jan J. Busschbach, PhD, Marc A. M. Mureau, MD, PhD

Published in: Annals of Surgical Oncology | Issue 13/2021

Excerpt

After a diagnosis of breast cancer has been made, a major choice a patient with early-stage breast cancer needs to make, along with her surgeon, is between breast-conserving surgery followed by radiation therapy (breast-conserving therapy [BCT]) or mastectomy, which may be followed by breast reconstruction (BR). In discussing the pros and cons of these options, quality-of-life considerations will be an important topic as there are no differences in survival rates.1 …

Van Maaren MC, de Munck L, de Bock GH, Jobsen JJ, van Dalen T, Linn SC, et al. 10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study. Lancet Oncol. 2016;17:1158–70.CrossRef

Tsoi B, Ziolkowski NI, Thoma A, Campbell K, O’Reilly D, Goeree R. Systematic review on the patient-reported outcomes of tissue-expander/implant vs autologous abdominal tissue breast reconstruction in postmastectomy breast cancer patients. J Am Coll Surg. 2014;218:1038–48.CrossRef

Schmidt ME, Wiskemann J, Steindorf K. Quality of life, problems, and needs of disease-free breast cancer survivors 5 years after diagnosis. Qual Life Res. 2018;27:2077–86.CrossRef

Yoon AY, Bozzuto L, Seto AJ, Fisher CS, Chatterjee A. A systematic review of utility score assessments in the breast surgery cost-analysis literature. Ann Surg Oncol. 2019;26:1190–201.CrossRef

Kouwenberg CAE, de Ligt KM, Kranenburg LW, Rakhorst H, de Leeuw D, Siesling S, et al. Long-term health-related quality of life after four common surgical treatment options for breast cancer and the effect of complications: a retrospective patient-reported survey among 1871 patients. Plast Reconstr Surg. 2020;146:1–13.CrossRef

Bennett KG, Qi J, Kim HM, Hamill JB, Pusic AL, Wilkins EG. Comparison of 2-year complication rates among common techniques for postmastectomy breast reconstruction. JAMA Surg. 2018;153:901–8.CrossRef

Kouwenberg CAE, Mureau MAM, Kranenburg LW, Rakhorst H, de Leeuw D, Klem T, et al. Cost-utility analysis of four common surgical treatment pathways for breast cancer. Eur J Surg Oncol. 2021;47(6):1299–1308. https://doi.org/10.1016/j.ejso.2020.11.130.

De Boer M, Van Leeuwen FE, Hauptmann M, Overbeek LIH, De Boer JP, Hijmering NJ, et al. Breast implants and the risk of anaplastic large-cell lymphoma in the breast. JAMA Oncol. 2018;4:335–41.CrossRef

Nelson JA, Dabic S, Mehrara BJ, Cordeiro PG, Disa JJ, Pusic AL, et al. Breast Implant-associated Anaplastic Large Cell Lymphoma Incidence: Determining an Accurate Risk. Ann Surg. 2020;272:403–9.CrossRef

10.

Cordeiro PG, Ghione P, Ni A, Hu Q, Ganesan N, Galasso N, et al. Risk of breast implant associated anaplastic large cell lymphoma (BIA-ALCL) in a cohort of 3546 women prospectively followed long term after reconstruction with textured breast implants. J Plast Reconstr Aesthet Surg. 2020;73:841–6.CrossRef

11.

Swanson E. Plastic surgeons defend textured breast implants at 2019 US Food and Drug Administration hearing: why it is time to reconsider. Plast Reconstr Surg Global Open. 2019;7:e2410.CrossRef

12.

Lee E, Khavanin N, He W, Darrach H, Kraenzlin F, Jenny H, et al. Public Perceptions on Breast Implant-Associated Anaplastic Large Cell Lymphoma. Plast Reconstr Surg. 2020;146:30–7.CrossRef

13.

Oliveri S, Ongaro G, Durosini I, Curigliano G, Pravettoni G. Breast implant-associated anaplastic large cell lymphoma: emotional impact and guidelines for psychological support. Breast Cancer Res Treat. 2020;181:221–4.CrossRef

14.

Heeg E, Jensen MB, Mureau MAM, Ejlertsen B, Tollenaar RAEM, Christiansen PM, et al. Breast-contour preserving procedures for early-stage breast cancer: a population-based study of the trends, variation in practice and predictive characteristics in Denmark and the Netherlands. Breast Cancer Res Treat. 2020;182:709–18.CrossRef

Title: Why Breast-Conserving Therapy Should be Considered Treatment of Choice in Early-Stage Breast Cancer Patients
Authors: Casimir A. E. Kouwenberg, MD, MSc
Leonieke W. Kranenburg, PhD
Jan J. Busschbach, PhD
Marc A. M. Mureau, MD, PhD
Publication date: 01-12-2021
Publisher: Springer International Publishing
Keywords: Mastectomy
Breast Cancer
Breast Cancer
Published in: Annals of Surgical Oncology / Issue 13/2021
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-021-10203-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Why Breast-Conserving Therapy Should be Considered Treatment of Choice in Early-Stage Breast Cancer Patients

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 13/2021

ASO Author Reflections: Perspectives in the Measurement of Rapid Turnover Proteins in Patients with Hepatocellular Carcinoma

ASO Author Reflections: Mesothelin Expression in Patients with Stage IV Colorectal Cancer: A New Potential Therapeutic Target

Significance of Circular FAT1 as a Prognostic Factor and Tumor Suppressor for Esophageal Squamous Cell Carcinoma

ASO Author Reflections: The Evolution of Treatment for Advanced Esophageal Cancer Invading the Aorta: The Impact of thoracic Endovascular Aortic Repair (TEVAR) on Clinical Outcome

Microsatellite Instability and Effectiveness of Adjuvant Treatment in pT1N1 Gastric Cancer: A Multicohort Study

Robotic Enucleation of a Large Gastroesophageal Junction Leiomyoma